Crossmark

Antithrombotic therapy after mitral valve repair: VKA or aspirin?

Crossref DOI link: https://doi.org/10.1007/s11239-018-1724-0

Published Online: 2018-08-21

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van der Wall, Sake J.

Olsthoorn, Jules R.

Heuts, Samuel

Klautz, Robert J. M.

Tomsic, Anton

Jansen, Evert K.

Vonk, Alexander B. A.

Sardari Nia, Peyman

Klok, Frederikus A.

Huisman, Menno V.
License Information

Text and Data Mining valid from 2018-08-21
More Information

Article History

First Online: 21 August 2018

Change Date: 10 September 2018

Change Type: Correction

Change Details: The original version of this article unfortunately contained a mistake in the author name. The co-author name should be Frederikus A. Klok instead of Frederik A. Klok. The original article has been corrected.

Compliance with Ethical Standards

:

: Frederikus A. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion. Menno V. Huisman reports research grants from ZONMW, Pfizer-BMS, Boehringer-Ingelheim and Daiichi-Sankyo as well as fees for lectures from Pfizer-BMS, Boehringer-Ingelheim and Daiichi-Sankyo. All other authors declare that they have no competing interests.

: The institutional review board of the LUMC, VUmc and MUMC approved the study protocol and waived the need for informed consent due to the observational design.